Swiss drugmaker Roche on Tuesday named a new head of its $13-billion-per-year diagnostics business and also said board member Peter Voser is stepping down to focus on his expanded duties as interim head of Swiss engineering group ABB.
Roche’s new diagnostics boss, Thomas Schinecker, fills a post that had been led for months on an interim basis by Michael Heuer, who is retiring. Roche’s diagnostics unit includes diabetes care, sophisticated laboratory equipment and tests aimed at personalizing cancer treatment.
With Schinecker, 44, Roche has looked inside the company to finally fill a key leadership position vacated last August by Roland Diggelmann. Schinecker began his career in 2003 as a trainee for Roche Diagnostics before moving up the ranks in jobs in the United States, Singapore, Austria, Sweden and Switzerland.
“Thomas Schinecker has broad and international experience in our business,” Roche CEO Severin Schwan said in a statement.
Roche’s head of group communications, Stephan Feldhaus, is also leaving in September, to be replaced by Barbara Schaedler, who is now head of public affairs at E.ON SE.
Voser had been on Roche’s board since 2011 but wants to dedicate more time as interim CEO of ABB, a post he has filled since Ulrich Spiesshofer left the robotics and automation company in April.
By John Miller
Source: Reuters
Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.
On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.
General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.
